Promising pCR Rates with Neoadjuvant Durvalumab Plus Platinum-based Chemotherapy Combined with ADC for Patients with Resectable NSCLC By Ogkologos - July 29, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NeoCOAST-2 study Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Pralsetinib September 28, 2021 Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... April 14, 2025 Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer May 28, 2020 Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 Load more HOT NEWS ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma Moxetumomab Approved by FDA for Hairy Cell Leukemia Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75
